Organization
Edgewise Therapeutics
8 clinical trials
Clinical trial
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of EDG-5506 on Safety, Biomarkers, Pharmacokinetics, and Functional Measures in Adults and Adolescents With Becker Muscular DystrophyStatus: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
An Open-Label Extension Study to Assess the Long-term Effect of EDG-5506 on Safety, Biomarkers, and Functional Measures in Adults and Adolescents With Becker Muscular DystrophyStatus: , Estimated PCD: 2028-03-01
Clinical trial
A 2-part Phase 2 Study of Safety, Pharmacokinetics and Biomarkers in Children With Duchenne Muscular Dystrophy Including a Randomized, Double-Blind, Placebo-Controlled Part A, Followed by an Open-Label Part BStatus: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
A Phase 2 Study to Evaluate the Effect of EDG-5506 on Safety, Pharmacokinetics, and Biomarkers in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene TherapyStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase 1b, Open-label Study of the Safety and Pharmacokinetics of EDG-5506 in Adults With Becker Muscular DystrophyStatus: Completed, Estimated PCD: 2024-03-01
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of EDG-7500 in Healthy AdultsStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
An Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of EDG-7500 in Adults With Obstructive Hypertrophic CardiomyopathyStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase 1, Open-label Study in Healthy Male Subjects of the Absorption, Metabolism, Excretion, and Pharmacokinetics of EDG-5506 and an Absolute Bioavailability Study Using Radiolabeled EDG-5506Status: Completed, Estimated PCD: 2023-04-06